Widely used:Recently Viewed
Clear All
Today’s Range
52 Week Range
Liquidity
Market cap
$86 Mln
P/E Ratio
30.11
P/B Ratio
2.36
Industry P/E
93.43
Debt to Equity
1.63
ROE
0.07 %
ROCE
--
Div. Yield
0 %
Book Value
--
EPS
0.15
CFO
$66.43 Mln
EBITDA
$103.08 Mln
Net Profit
$70.33 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Zynex (ZYXI)
| -69.16 | -66.67 | -70.06 | -81.06 | -24.68 | -22.44 | 35.02 |
|
BSE Sensex
| -1.72 | 1.54 | -1.46 | 6.66 | 9.95 | 20.78 | 10.53 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Zynex (ZYXI)
| -26.26 | -21.71 | 70.88 | -25.93 | 71.03 | 167.69 | -7.51 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 16.45 | 11,350.65 | 16.03 | 12.69 | |
| 73.32 | 9,922.23 | 95.45 | 2.52 | |
| 166.16 | 9,319.12 | -- | -25.23 | |
| 280.14 | 10,500.20 | 778.91 | 1.2 |
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a... dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. Address: 9655 Maroon Circle, Englewood, CO, United States, 80112 Read more
Founder, President, CEO & Chairman
Mr. Thomas Sandgaard
Founder, President, CEO & Chairman
Mr. Thomas Sandgaard
Headquarters
Englewood, CO
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Zynex Inc (ZYXI) stood at $ 146 Mln as on 30-Sep-24
The share price of Zynex Inc (ZYXI) is $2.47 (NASDAQ) as of 21-Mar-2025 13:38 EDT. Zynex Inc (ZYXI) has given a return of -24.68% in the last 3 years.
Zynex Inc (ZYXI) has a market capitalisation of $ 86 Mln as on 20-Mar-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Zynex Inc (ZYXI) is 2.36 times as on 20-Mar-2025, a 34% discount to its peers’ median range of 3.58 times.
The P/E ratio of Zynex Inc (ZYXI) is 30.11 times as on 20-Mar-2025, a 68% discount to its peers’ median range of 93.43 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Zynex Inc (ZYXI) and enter the required number of quantities and click on buy to purchase the shares of Zynex Inc (ZYXI).
Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. Address: 9655 Maroon Circle, Englewood, CO, United States, 80112
The CEO & director of Mr. Thomas Sandgaard. is Zynex Inc (ZYXI), and CFO & Sr. VP is Mr. Thomas Sandgaard.
There is no promoter pledging in Zynex Inc (ZYXI).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,135
|
|
|
1,050
|
|
|
992
|
|
|
932
|
| Zynex Inc. (ZYXI) | Ratios |
|---|---|
|
Return on equity(%)
|
14.01
|
|
Operating margin(%)
|
4.57
|
|
Net Margin(%)
|
2.49
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Zynex Inc (ZYXI) was $0 Mln.
$-0.10
(
